![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Oncodesign announced today that the company has acquired exclusive commercialization rights to distribute the world’s most comprehensive collection of human colorectal cancer models directly developed from patient’s tumors. Oncodesign’s clients can now access the entire collection to evaluate therapeutic compounds in house or to carry out preclinical studies with Oncodesign. This new collection has integrated Oncodesign’s Chi-Mice(R) platform, designed to provide state-of-the-art preclinical models from human samples. The Chi-Mice(R) platform includes both reconstituted human immune system models on NSG/NOG mice and models xenografted with patient-derived tumors. “This collection is the result of a five year research program, and is the most comprehensive worldwide in terms of the range of genetic heterogeneity and characterization. It marks a breakthrough in the evaluation of colorectal cancer therapies,” explained Philippe Genne, president and CEO of Oncodesign. “The CReMEC collection ensures low-passage experimental models to fit the clinical reality. This is all the more relevant since preclinical research usually relies on cell lines that may be many years old, grown in tissue culture and then grafted onto mice. Cell lines may drift into different genetic profiles and are not reliable enough to evaluate anticancer therapies.”
CReMEC brings together highly qualified and complementary skills from world-class French institutes, three pharmaceutical companies, and Oncodesign as project leader. The EUR 5.4 million program has been developed to meet industrial requirements and strict guidelines were observed from conception to characterization. A full range of characterization is available with each model. Clinical, molecular, pharmacological and histological data have been carefully collected and gathered in a dedicated database, in parallel with a biobank of more than 5,000 samples. The CReMEC collection and derivatives represent a valued basis for Oncodesign’s clients and academic institutions now conducting research projects with these resources.
Based on this initial success, Oncodesign says the consortium is considering the development of a dedicated national platform. The challenge is to provide patient-derived cancer models for any cancer pathology to meet unsatisfied needs in cancer research.
About Oncodesign(R)
Oncodesign Biotechnology is dedicated to the discovery of effective anti-cancer therapies. Its strategic focus is two-fold: experimentation towards new anti-cancer therapies and implementation of discovery programs in partnership with the pharmaceutical industry. Oncodesign’s prime areas of expertise cover pharmacology, imaging and medicinal chemistry together with rigorous project management.
Oncodesign’s experimentation activity covers three complementary modules: the development of experimental in vivo chimeric models (patient-derived models and reconstituted human immune system models) in its Chi-Mice(R) module; non-invasive, multi-modal pharmaco-imaging (SPECT, MRI, PET) and biomarker identification and validation in its activities with the PharmImage(R) consortium which it leads; conventional in vitro and in vivo pharmacology for early proof of concept evaluation. Oncodesign markets a wide range of products and services based on these three areas of technological know-how for the validation of anticancer therapies.
The drug and imaging biomarker discovery activity at Oncodesign is based on its chemistry technology, Nanocyclix(R) for the synthesis and optimization of new compounds for therapeutic or diagnostic use. Nanocyclix (R) gives access to potent and selective kinase inhibitors with good drug-like properties. Coupled with Oncodesign’s three other technological specialties, Nanocyclix(R) enables Oncodesign to offer its partners a unique innovative platform applicable from target to patient in a risk-sharing relationship.
Founded in 1995, and led by Dr Philippe Genne, Oncodesign is based in Dijon, France. It employs 55 people including 14 PhDs. Dr Jan Hoflack was appointed as Chief Scientific Officer in 2009. The company is the European leader in pre-clinical evaluation of anticancer therapies.
For more information, see: http://www.oncodesign.com.
